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Previous studies have shown that copy-number variants (CNVs) contribute to the risk of complex developmental phenotypes. However,
the contribution of global CNV burden to the risk of sporadic congenital heart disease (CHD) remains incompletely defined. We gener-
ated genome-wide CNV data by using Illumina 660W-Quad SNP arrays in 2,256 individuals with CHD, 283 trio CHD-affected families,
and 1,538 controls. We found association of rare genic deletions with CHD risk (odds ratio [OR] ¼ 1.8, p ¼ 0.0008). Rare deletions in
study participants with CHD had higher gene content (p ¼ 0.001) with higher haploinsufficiency scores (p ¼ 0.03) than they did in
controls, and they were enriched with Wnt-signaling genes (p ¼ 1 3 105). Recurrent 15q11.2 deletions were associated with CHD
risk (OR ¼ 8.2, p ¼ 0.02). Rare de novo CNVs were observed in ~5% of CHD trios; 10 out of 11 occurred on the paternally transmitted
chromosome (p ¼ 0.01). Some of the rare de novo CNVs spanned genes known to be involved in heart development (e.g., HAND2 and
GJA5). Rare genic deletions contribute ~4% of the population-attributable risk of sporadic CHD. Second to previously described CNVs at
1q21.1, deletions at 15q11.2 and those implicatingWnt signaling are the most significant contributors to the risk of sporadic CHD. Rare
de novo CNVs identified in CHD trios exhibit paternal origin bias.Introduction
In the human genome, rare copy-number variants (CNVs),
generally considered to be those with <1% population fre-
quency, have recently been the focus of increasing atten-
tion as potential causative factors of complex diseases.
Considered together, such individually rare CNVs are suffi-
ciently common that case-control comparisons of their
collective frequency can be conducted in large sample
sets. Such comparisons have revealed association between
rare CNV burden, in particular rare CNVs that overlap
genes (or rare genic CNVs), and disease risk in a variety
of neuropsychiatric and developmental conditions.1–4
Congenital heart disease (CHD) is the most common
congenital abnormality: it has an incidence of approxi-
mately 7 in 1,000 live births.5 CHD can occur as a compo-
nent of a large number of chromosomal and Mendelian
malformation syndromes, but in 80% of cases, it occurs
as a sporadic condition that exhibits high heritability.6
Tetralogy of Fallot (TOF [MIM 187500]) is the most
common cyanotic CHD phenotype and occurs in 1 in
2,500 live births.5 TOF is considered an abnormality of
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The Americanphalad deviation of the outlet septum; this causes over-
riding of the aorta, ventricular septal defects, right ventric-
ular outflow tract obstruction, and right ventricular
hypertrophy. Prior to the modern cardiac surgical era,
severe CHD carried a high mortality (for example, 80% of
children born with TOF died before their tenth birthday),
and therefore, genetic investigation of sporadic, nonsyn-
dromic CHD has generally focused on rare and de novo
variants. Greenway et al. reported a genome-wide rare de
novo CNV burden of ~10%—it involved 10 different loci
in 114 nonsyndromic TOF trios (TOF probands and their
respective unaffected parents).7 However, only one locus
(1q21.1) identified in that study has been replicated in
an independent cohort thus far.8 Recently, Cooper et al.
analyzed rare CNV burden in a large number of children,
including 575 cases with CHD as a component of their
phenotype, referred for genetic evaluation of intellectual
disability.4 Children with CHD were shown to have
a significantly increased burden of large CNVs (>400 kb)
(p ¼ 6.45 3 105) than were children with autism spec-
trum disorder. However, the population studied by these
investigators included many cases with recognized dele-
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Williams [MIM 194050] and DiGeorge [MIM 188400]
syndromes); mainly large deletions were studied, and the
population was not primarily ascertained for CHD.
Here, we address the disease risk associated with the
global burden of CNVs > 100 kb in a case population
that is nonsyndromic, non-Mendelian (i.e., sporadic),
and ascertained on the basis of CHD. Our prior hypothesis
was that rare genic CNVs would show association with
CHD risk.We present locus-specific and functional annota-
tion enrichments associated with CHD risk, and we
propose dosage-sensitive genes for CHD. In addition,
we examine the genome-wide burden of rare de novo
CNVs > 30 kb in a cohort of CHD trios.Subjects and Methods
Study Subjects and Sample Collections
CHD-affected participants (51% male and 49% female; median
age ¼ 10 years; interquartile range ¼ 1–25 years) of European
ancestry, as well as their parents and siblings (when available),
were recruited frommultiple centers in the UK (Newcastle, Bristol,
Leeds, Liverpool, Nottingham, Leicester, and Oxford), Germany
(Erlangen), Belgium (Leuven), and Australia (Sydney). Ethical
approval was granted from the local institutional review boards,
and informed consent was obtained from all participants (or
from a parent or guardian in cases where the subjects were too
young to consent themselves). All participants with CHD were
screened for DiGeorge syndrome, Williams-Beuren syndrome,
and other major chromosomal aberrations (e.g., trisomy 21
[MIM 190685] and trisomy 18) known to cause CHD; those found
with such anomalies were excluded from further study. Case ascer-
tainment in Bristol, Leeds, and Liverpool was principally focused
on TOF, whereas case ascertainment in other centers included all
CHD phenotypes. Thus, TOF was relatively overrepresented in
our cohort. Case ascertainment was not focused on multiplex
families; fewer than 1% of probands had an affected first-degree
relative with CHD. Control subjects consisted of unrelated healthy
European-ancestry individuals from a French population cohort.
DNA samples from cases were extracted from blood (85%) and
saliva (15%), and all DNA samples from controls were extracted
from blood; quality-control (QC) assessment of CNV calls indi-
cated no significant systematic difference between DNA derived
from blood or from saliva.
Genotyping, QC Criteria, and CNV Detection on
Illumina 660W SNP Arrays
A total of 2,896 CHD cases, 747 unaffected family members, and
856 unrelated controls were typed on the Illumina 660W-Quad
SNP platform at the Centre National de Ge´notypage (Evry Cedex,
France), and normalized total intensity and genotype data were
obtained. For each sample, SNP QC analyses were carried out in
PLINK.9 Samples with genotyping call rates < 98.5%, average
heterozygosity outside the range of [0.31, 0.33], and gender
mismatches and those that failed to cluster with the Phase II
HapMap CEU (Utah residents with ancestry from northern and
western Europe from the CEPH collection) individuals were
excluded. Genome-wide identity-by-descent (IBD) sharing was
calculated on all probands, and only one individual from each
pair of related probands (mean proportion of alleles shared identi-
cally by descent > 0.1; n ¼ 18) was included in the analyses. Addi-490 The American Journal of Human Genetics 91, 489–501, Septembtionally, intensity QC parameters were applied, and samples were
excluded when they failed one of the following criteria: a standard
deviation of autosomal log R ratio (LRR)> 3.0, a GC-wave factor of
the LRR outside the range of [0.1, 0.1],10 or a standard deviation
of B-allele frequency (BAF) > 0.15 after GC correction.11 A total of
2,256 CHD cases, 697 unaffected family members, and 841 unre-
lated controls were included in the final analyses. The phenotype
distribution of the CHD cases can be found in Table S1, available
online. For case-control CNV-burden comparison, the Quan-
tiSNP11 algorithmwas used as the primary CNV detection method
and PennCNV10 was used as the confirmatory method. Rare de
novo CNV detection in probands and their respective unaffected
parents was performed with PennCNV joint calling,10 and Quan-
tiSNPwas used for confirmation. For probands and their respective
parents, both PennCNV and QuantiSNP raw data sets were further
inspected manually within all the putative de novo CNV spans, as
well as in the flanking regions, so that the possibility of false nega-
tives in the parental samples could be ruled out. All CNV coordi-
nates were mapped to NCBI build 36.1 (hg18). The coordinates
for RefSeq genes and segmental duplications12 were downloaded
from the UCSC Genome Browser.13 CNVs were further analyzed
with custom R scripts and the ‘‘join genomic interval’’ tool on
Galaxy14 and were visualized in the UCSC Genome Browser.
CNV Validation
Affymetrix 6.0 SNP arrays, comparative genomic hybridization
(CGH) arrays, and multiplex ligation-dependent amplification
(MLPA) were used for confirming CNV calls that were made on
the discovery platform (Illumina 660W-Quad). A random subset
of CHD cases (n ¼ 198) that had been analyzed on the discovery
platform was also typed on the Affymetrix 6.0 platform and
analyzed with the Birdseye algorithm from the BirdSuite
package.15 CGH was performed for all rare de novo CNVs > 30kb,
CNVs in candidate loci, and recurrent CNVs that were suspected
to be artifacts (because of certain properties of the genomic
regions on the discovery platform) when DNA was available and
when the region was adequately covered on the CGH platform.
All remaining CNVs were validated with MLPA.
For the CGH experiments, 4x44K (ISCA v.2) and 2x105K Agilent
(Santa Clara, CA, USA) arrays were purchased from BlueGnome
(Cambridge, UK). CHD case and control DNA samples (1 mg
each) were labeled, purified, hybridized, and washed with reagents
according to BlueGnome protocol (Cambridge, UK; see Web
Resources). Control DNA samples (catalog numbers G1471 and
G1521) were purchased from Promega (Madison, WI, USA). A
GenePix 4000B laser scanner (Axon Instruments, CA, USA) was
used for exciting the hybridized fluorophores and for scanning
the images, which were then quantified and normalized with
the default settings and analyzed on hg18 (NCBI build 36.1)
with BlueFuse Multi software (BlueGnome, Cambridge, UK) and
visualized in the UCSC Genome Browser.
MLPA assays were performed with custom-designed synthetic
probes ordered from Integrated DNA Technology (IA, USA) and
with the P200 MLPA kit from MRC-Holland (Amsterdam, The
Netherlands). A minimum of two probes per CNV locus were de-
signed with the MAPD software16 in conjunction with the UCSC
Extended DNA utility.13 Each MLPA assay contained a total of 11
synthetic probes with sizes ranging from 100–140 nt. MLPA reac-
tions were carried out with the MRC-Holland protocol (see Web
Resources). MLPA products were resolved on an ABI 3730xl
(Applied Biosystems, CA, USA) and analyzed with GeneMarker
v.1.85 software (SoftGenetics, PA, USA).er 7, 2012
Table 1. Frequency of Deletions in Cases and Controls
CNV Category
CHD
Cases Controls
Fold Change of CHD
Cases vs. Controls p Value
Rare genic 7.8% 4.4% 1.8 0.0008
Rare 10.5% 8.3% 1.3 0.07
Common genic 6.3% 6.5% 1.0 0.80
Common 21.5% 21.8% 1.0 0.88
All genic 13.7% 10.8% 1.3 0.04
All 29.3% 28.9% 1.0 0.82
Statistically significant findings are shown in bold. The following abbreviations
are used: CNV, copy-number variant; and CHD, congenital heart disease.Statistical Analysis
We compared the frequency of CNVs in case and control groups
by using a two-sided Fisher’s test. To make some allowance for
multiple testing, we also calculated empirical p values from
1,000 random permutations of disease status by taking the
minimum p value obtained over 36 tests to account for the
testing of six CNV categories (see Table 1) times three CNV sizes
(>100 kb, >500 kb, and >1 Mb) times two CNV types (duplica-
tions and deletions). CNV length and the number of genes
spanning each CNV in cases versus controls were assessed with
two-sided permutation tests, which compare the observed t
statistic (normalized difference between means) with the t statis-
tics from 10,000 random replicates of relabeling of cases and
controls. Haploinsufficiency scores of the genes spanned by
CNVs in cases and controls were obtained from a published
source17 and compared with the use of a two-tailed Mann Whit-
ney U test. Population attributable risk (PAR) was calculated with
the following formula: 100(P(OR-1))/(1 þ (P(OR1))), in which P
is the proportion of control population with the CNVs and OR
is the odds ratio. The frequency of rare de novo CNVs was ascer-
tained in 283 TOF trios. We determined the parental origin of
the de novo CNV by examining the mismatches between the
BAF of each SNP in the proband and both parents within each
CNV region. We compared the frequency of each parental origin
by using a binomial probability distribution to obtain a two-tailed
p value. All statistical tests were performed with the R statistical
package. Because our study included substantial numbers of
CHD cases with a relatively homogeneous phenotype (TOF), we
decided a priori to explore heterogeneity between the group
with TOF and the group with other types of CHD. We considered
that there were insufficient numbers of CHD cases with any other
homogeneous phenotype to permit additional valid subgroup
analyses.Results
CNV Validation and Inclusion Criteria
We used stringent filtering measures for case-control
genome-wide CNV-burden analyses (size > 100 kb with
Bayes factor11 > 100) in order to ensure comparability of
detection between individuals ascertained from multiple
centers. Initially, 4,551 autosomal CNV calls (1,217 dele-
tions and 3,334 duplications) met these inclusion criteria
on the Illumina 660W-Quad chip. We subjected 87 dele-
tion calls and 216 duplication calls to validation (87%
were randomly selected, and the remainder were targeted
to CNVs in candidate loci and recurrent calls that were sus-
pected to be artifacts) with one or more independent
experiments (Affymetrix 6.0, array CGH, or MLPA). The
resulting positive validation rates were 85% and 34% for
deletions and duplications, respectively. On the basis of
this validation data, we identified a number of regions
that could not be genotyped reliably (see Table S2), and
after these regions were excluded, 74 out of 74 (100%) dele-
tion calls and 62 out of 62 (100%) duplication calls were
successfully validated by Affymetrix 6.0, array CGH, or
MLPA. In total, 1,077 out of 1,217 (88%) deletion calls
and 778 out of 3,334 (23%) duplication calls that met
the initial filtering criteria remained (after the unreliableThe Americanregions were excluded), and they were incorporated into
the final analyses.
CNV Burden in CHD Cases and Controls
The frequency of CNVs was compared between 2,256 CHD
cases (808 TOF and 1,448 other CHDs) and 841 ethnically
matched unrelated controls. Although our principal prior
hypothesis was that rare genic CNVs would show associa-
tion with CHD risk, we also examined the following
CNV sets: all CNVs, genic CNVs, rare CNVs, common
CNVs, and common genic CNVs. Genic CNVs were
defined as those that overlap with RefSeq transcription
boundaries. Rare CNVs were defined as those that occur
with <1% frequency and have minimum (<20%) overlap
with CNVs in the compared group—in effect, CNVs that
are unique to the case or control group. We also confirmed
that all CNVs deemed rare in our study had not been previ-
ously reported at >1% frequency in control populations
described in the Database of Genomic Variants (DGV).
Common CNVs were defined as those shared (>20% over-
lap) between case and control groups.
There was a highly significant (1.8-fold) difference in
rare genic-deletion burden between CHD cases and
controls (p ¼ 0.0008; Table 1) and no apparent heteroge-
neity in risk between TOF and other CHDs. This associa-
tion remained significant after permutation-test-based
correction for 36 comparisons (empirical corrected p ¼
0.013). The strong association with rare-genic-deletion
burden was responsible for the fact that borderline signifi-
cant association was observed in the subgroups overlap-
ping rare genic deletions (all rare deletions [p ¼ 0.07];
and all genic deletions [p ¼ 0.04]), but these became
nonsignificant after correction for multiple testing. There
was no difference in the frequency of common deletions,
or of overall deletion burden, between case and control
groups (Table 1). The excess burden of rare genic deletions
corresponds to a population-attributable risk (PAR) of
~3.5% for CHD. Given the difference in frequency of rare
genic deletions> 100 kb in cases and controls, we explored
association between larger rare genic deletions and CHD.
We observed an apparent trend toward a greater (2.5-
fold) difference in the frequency of large (>500 kb) rareJournal of Human Genetics 91, 489–501, September 7, 2012 491
Table 2. Frequency of Duplications in Cases and Controls
CNV Category
CHD
Cases Controls
Fold Change of CHD
Cases vs. Controls p Value
Rare genic 8.7% 8.1% 1.1 0.61
Rare 10.5% 10.2% 1.0 0.89
Common genic 10.2% 9.5% 1.0 0.59
Common 12.1% 12.1% 1.0 1.0
All genic 18.0% 16.3% 1.1 0.29
All 21.0% 20.7% 1.0 0.88
The following abbreviations are used: CNV, copy-number variant; and CHD,
congenital heart disease.
Table 3. CNV Size in Cases versus Controls
Copy Number Group
Mean
Length (bp)
Cases vs. Controls
Ratio p Value
Deletions TOF cases 285,657 1.3 0.024
CHD cases 337,288 1.6 0.022
controls 213,262
Duplications TOF cases 517,326 1.1 0.312
CHD cases 472,382 1.0 0.793
controls 462,125
The following abbreviations are used: TOF, Tetralogy of Fallot; and CHD,
congenital heart disease. p values were generated with a two-sided permuta-
tion test with 10,000 replicates.deletions between cases and controls (p ¼ 0.024); this
difference was yet more marked (3.9-fold difference)
when only >1 Mb deletions were considered (p ¼ 0.017),
and there was no heterogeneity between TOF and other
CHDs. However, the small number of larger deletions
precluded formal tests for heterogeneity between these
risks. No difference was found between cases and controls
in the frequency of large common deletions.
We did not detect any difference in the frequency of
either rare or common duplications (see Table 2). We
detected an excess of large (>500 kb) genic duplications
in TOF cases compared to controls (a 1.9-fold difference;
p ¼ 0.01); this effect was solely due to a single locus
(1q21.1) whose effect on TOF risk has been previously
documented.8
Properties and Functional Impact of CNVs
We compared the size of deletions and duplications in
cases and controls (see Table 3) and observed larger dele-
tions in cases than in controls (a 1.3-fold difference and
p ¼ 0.024 for TOF; a 1.6-fold difference and p ¼ 0.022
for other CHDs) but no difference in the length of duplica-
tions. Comparing both TOF and other CHG cases to
controls, we found significant differences in the numbers
of genes that were spanned by both deletions and duplica-
tions (Table 4). In both case groups, these effects were
driven by rare CNVs. For rare deletions, there was a 2.6-
fold higher number of genes (p ¼ 0.006) for TOF and
a 3.7-fold higher number of genes (p ¼ 0.001) for other
CHDs. For rare duplications, there was a 2.8-fold higher
number of genes (p ¼ 1.0 3 104) for TOF and a 1.9-fold
higher number of genes (p ¼ 0.006) for other CHDs. The
number of genes spanned by common CNVs did not
differ between cases and controls. Furthermore, genes
encompassed by deletions in CHD cases were associated
with higher haploinsufficiency scores17 (p ¼ 0.02) (see
Figure S1). This effect was also due to the genes encom-
passed by rare deletions (p ¼ 0.03) and not by common
deletions (p ¼ 0.40). No difference was observed in the
haploinsufficiency scores of the genes encompassed by
duplications in cases compared to controls (p ¼ 0.44).
The list of genes spanned by rare deletions that were asso-492 The American Journal of Human Genetics 91, 489–501, Septembciated with high haploinsufficiency scores, as well as recur-
rent genes overlapped by both rare deletions and rare
duplications in CHD cases, can be found in Tables S3–S5.
In order to identify pathway or ontology overrepresenta-
tion in functional regions, we performed Genomic Region
Annotation Enrichment analysis (GREAT v.1.8.218) on rare
deletions and rare duplications in 2,256 CHD cases.
Analysis was carried out with default settings and the
entire genome as background. GREATanalysis on rare dele-
tions resulted in statistically significant enrichment genes
in the Wnt-signaling pathway (2.9-fold enrichment;
p ¼ 1.2 3 105) and implicated 13 genes (CDH18 [MIM
603019], CDH2 [MIM 114020], CTBP1 [MIM 602618],
CTNNB1 [MIM 116806], FAT1 [MIM 600976], LRP5L,
NFATC1 [MIM 600489], PCDH15 [MIM 605514], PCDHB7
[MIM 606333], PCDHB8 [MIM 606334], PRKCB [MIM
176970], PRKCQ [MIM 600448], and WNT7B [MIM
601967]) in this pathway; there was involvement of Wnt
genes in 28 out of 238 (12%) CHD cases with rare dele-
tions. Phenotypes of these individuals were TOF (n ¼ 11),
atrial septal defect (n ¼ 7), transposition of the great
arteries (n¼ 3), atrioventricular septal defect (n¼ 2), coarc-
tation of the aorta (n ¼ 2), aortic stenosis (n ¼ 1), congen-
itally corrected transposition of the great arteries (n ¼ 1),
and ventricular septal defect (n¼ 1). No significant enrich-
ment was found for any other functional category. We did
not find pathway or gene-ontology overrepresentation in
the rare duplications.
Deletions in 15q11.2 Are Associated with CHD
Twelve 15q11.2 deletions were identified in our CHD
cohort (n ¼ 2,256), and a critical region encompassed
four RefSeq genes: TUBGCP5 (MIM 608147), CYFIP1
(MIM 606322), NIPA2 (MIM 608146), and NIPA1 (MIM
608145) (see Figure 1). The phenotypes of these partici-
pants were complex left-sided malformations (n ¼ 3),
coarctation of the aorta (n ¼ 3), atrial septal defect
(n ¼ 2), ventricular septal defect (n ¼ 2), total anomalous
pulmonary venous drainage (n ¼ 1), and TOF (n ¼ 1)
(see Table 5 for details). We found one such deletion in
1,538 controls (841 unrelated controls and 697 unaffecteder 7, 2012
Table 4. Number of Genes per CNV in Cases versus Controls
Copy Number CNV Category TOF Mean CHD Mean Control Mean
TOF Cases vs. Controls CHD Cases vs. Controls
Ratio p Value Ratio p Value
Deletions all 1.7 2.5 1.0 1.7 0.009 2.5 3 3 104
rare 3.5 5.1 1.4 2.6 0.006 3.7 0.001
common 0.8 1.1 0.8 1.0 0.982 1.3 0.325
Duplications all 4.5 3.7 2.8 1.6 0.005 1.3 0.031
rare 6.1 4.1 2.2 2.8 1 3 104 1.9 0.006
common 3.2 3.4 3.3 1.0 0.829 1.0 0.878
The following abbreviations are used: CNV, copy-number variant; TOF, Tetralogy of Fallot; and CHD, congenital heart disease. p was generated with a two-sided
permutation test with 10,000 replicates.family members). Therefore, 15q11.2 deletions were more
frequent in CHD cases than in controls (12 out of 2,256 for
cases versus 1 out of 1,538 for controls; OR¼ 8.2; p¼ 0.02).
Recurrent CNVs at Candidate Locus 8p23.1 in CHD
We observed five rare CNVs (four deletions and one dupli-
cation) at the candidate 8p23.1 locus; the smallest deletion
spanned four RefSeq genes: GATA4 (MIM 600576), NEIL2
(MIM 608933), FDFT1 (MIM 184420), and CSTB (MIM
601145) (see Figure 2). No overlapping CNV was found
in our 1,538 controls or in the control populations that
have been cataloged in the DGV.
Rare De Novo CNV Burden and Paternal Origin Bias
in TOF Trios
In 283 TOF probands, we used PennCNV joint calling10 to
identify 13,375 putative CNV calls that did not occur in
their respective unaffected parents. PennCNV calls that
were previously observed in polymorphic frequency19The Americanand found with a frequency > 0.1% in our 1,538
controls, as well as calls that were not confirmed with
QuantiSNP (regardless of Bayes factor11) and those with
length < 30 kb, were excluded from further analysis (see
Figure S2 for details). We subjected all putative rare de
novo CNVs (n ¼ 28) to confirmation with an independent
method (Affymetrix 6.0, array CGH, or MLPA), and ~50%
(13/28) were successfully validated. We thus observed
rare de novo CNVs > 30 kb in ~5% (13/283) of our TOF
trios. Rare de novo CNVs were identified in loci (1q21.1,
3q29, and 4q34) that have been associated with isolated
or syndromic TOF or other CHDs, as well as in regions
(3q13.11, 5q14, 5q35.3, 6q27, 9p22.2, 16q11.2, 16q24.2,
19p13.3, and 22q12.3) that have not been previously
described to be relevant to the risk of TOF (Table 6). We
also investigated the parental origin of the de novo CNVs
identified. In 10 of 11 individuals in whom this could be
unequivocally determined, the CNV was on the paternal
allele (see Tables 6 and S6). Thus, we identified paternalFigure 1. Recurrent Rare Deletions in
15q11.2
Twelve deletions (shown as red bars in the
UCSC Genome Browser) were identified in
three individuals with complex left-sided
malformations (L-sided), three with coarc-
tation of the aorta (CoA), two with ventric-
ular septal defects (VSDs), two with atrial
septal defects (ASDs), one with total
anomalous pulmonary venous drainage
(TAPVD), and one with TOF. RefSeq genes,
segmental duplications, and coverage of
the Illumina 660W platform in the region
are shown. The smallest deletions encom-
pass four RefSeq genes: TUBGCP5, CYFIP1,
NIPA2, and NIPA1.
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Table 5. Phenotype Characteristics of CHD Individuals with 15q11.2 Deletions
Family ID Sex
Age
(Years) Chr Start Length Cardiac Phenotype
Extracardiac
Phenotype
GOCHD-2099.1 female N/A 15 20,303,106 332,779 atrial septal defect none
OX-1232.1 male 9 15 20,388,584 229,594 complex left sided none
OX-941.1 male 8 15 20,321,135 297,043 coarctation of the aorta none
LEU-111.1 male 27 15 20,314,760 321,125 complex left sided Crohn disease
NOTT-301.1 male 6 15 18,837,563 1,798,322 coarctation of the aorta none
NOTT-421.1 female 21 15 20,384,417 251,468 complex left sided none
NOTT-577.1 male <1 15 18,802,207 2,263,748 total anomalous pulmonary venous drainage none
NOTT-772.1 female 1 15 20,314,760 321,125 VSD (muscular)/ASD (secundum)/PDA none
SYD-1200.1 female 4 15 20,388,584 240,866 atrial septal defect none
SYD-1366.1 male 3 15 20,384,417 251,468 coarctation of the aorta none
SYD-443.1 female 2 15 20,384,417 251,468 ventricular septal defect none
CHA-549.1 male N/A 15 20,314,760 321,125 Tetralogy of Fallot none
Inheritance status could not be determined because none of the parental samples were available for analysis. The following abbreviations are used: Chr, chromo-
some; N/A, not available; VSD, ventricular septal defect; ASD, atrial septal defect; and PDA, patent ductus arteriosus.origin bias in rare de novo CNVs in TOF trios (p ¼ 0.01).
Because paternal origin bias has been previously reported
in rare de novo CNV occurrences that were not mediated
by segmental duplications (SDs),20,21 we additionally
looked for SDs within the vicinity of the breakpoints of
our de novo findings. Two out of 13 rare de novo CNV
breakpoints coincided with a pair of SDs in direct orienta-
tion (see Figure S3). Thus, 85% of the rare de novo CNVs
identified in this study were not mediated by SDs.
Recurrent Rare CNVs Overlapping De Novo CNV Loci
In the remaining 1,987 CHD cases, we found additional
rare CNVs that overlapped rare de novo CNVs present in
our TOF trios at 1q21.1 (as previously described8), 4q34
(HAND2 [MIM 602407]), 5q14.2 (EDIL3 [MIM 606018]),
and 5q35.3 (CNOT6 [MIM 608951]) (see Figure 3). In addi-
tion, we observed rare CNVs that overlapped with the rare
de novo CNVs previously identified in 114 TOF trios
by Greenway et al.7 at 1q21.1, 4q22.1 (PPM1K [MIM
611065]), and 7p21.3 (see Figure 4). Some of these recur-
rent CNVs (in 1q21.1, 4q34, and 7p21.3) were found to
be inherited from an unaffected parent, whereas the inher-
itance status of the remaining CNVs could not be deter-
mined because of the unavailability of parental samples.
Discussion
In one of the largest studies of CHD genetics thus far, we
performed a genome-wide investigation of CNVs > 100 kb
in sporadic, nonsyndromic CHD. Our data show that rare
deletions, in particular rare genic deletions, are associated
with both TOF and other CHDs and that they account
for 3%–4% of the PAR of each condition. We further
demonstrated significant excess of recurrent deletions at494 The American Journal of Human Genetics 91, 489–501, Septemb15q11.2 and of rare deletions involving Wnt-signaling
genes. Rare deletions or duplications spanning a larger
number of genes confer higher risk of CHD, and rare dele-
tions in CHD cases tend to be larger and encompass genes
with higher haploinsufficiency scores.17 Additionally, de
novo CNVs occurred in 5% of our trio families, implicating
candidate and novel genes for CHD.
Previous large studies of CNVs in psychiatric and devel-
opmental phenotypes have demonstrated an increased
burden of rare CNVs (the greatest effects were observed
in single-occurrence and de novo CNVs),1,2,22 larger CNV
size, and higher number of genes spanned by rare CNVs
in cases compared to controls.1,3,4 The study performed
by Cooper et al. (involving 15,767 cases of developmental
delay and 8,329 controls) had data on 575 cases with CHD
as a component of their phenotype and showed that
CNVs > 400 kb with <1% frequency were present in
around 25% of these cases.4 By contrast, 13.6% of our
CHD cases had such CNVs; there was a highly comparable
control frequency between both studies (11.5% in Cooper
et al.; 10.8% in the present study). This most likely reflects
the different ascertainment of the two cohorts; in the
study of Cooper et al., they were chiefly ascertained
through referral with a diagnosis of intellectual disability
or developmental delay, and in our study, they were ascer-
tained through pediatric and adult CHD clinics. Thus, our
study is likely to provide more representative estimates of
the contribution of CNVs to the population burden of
CHD. Our findings complement these previous studies in
providing evidence of the pathogenicity of rare CNVs
and their contribution to common complex diseases,
including CHD. In agreement with previous studies, our
data suggest that the more genes spanned by a CNV, the
greater its potential to be pathogenic. Our study also showser 7, 2012
Figure 2. Recurrent Rare CNVs in the
Candidate 8p23.1 Locus
(A and B) Four deletions were identified in
one individual with an atrioventricular
septal defect (AVSD), onewith a ventricular
septal defect (VSD), and two with TOF (all
shown as red bars). The smallest deletion
encompasses the last five exons of GATA4
and the whole coding regions of NEIL2
and FDFT1 (shown in B). In addition, an
overlapping duplication was identified in
one participant with a bicuspid aortic
valve with aortic regurgitation (AR) (blue
bar). The parental samples of these people
are not available for analysis.that cases have higher haploinsufficiency scores17 of the
genes encompassed by rare deletions than do controls.
Haploinsufficient genes have formerly been shown to
have biased evolutionary and functional properties. They
are much more highly conserved, highly expressed during
early development, and highly tissue specific.
We further identified an overrepresentation of Wnt-
signaling-pathway genes among those spanned by rare
deletions found in CHD cases. Wnt signaling regulates
diverse cellular processes, such as gene transcription and
cell proliferation, migration, polarity, and division.23,24
Both the classic canonical Wnt-signaling pathway involv-
ing beta-catenin and the noncanonical branches of the
pathway independent of beta-catenin are involved in a
coordinated fashion at all stages of cardiac specification,
differentiation, and development.23 Several model organ-
isms with mutations in Wnt-signaling-pathway genes
exhibit CHD,25,26 yet evidence to date for the involvement
of the Wnt pathway in human CHD has been sparse.
We found an association between CHD and deletions of
the 15q11.2 region (OR ¼ 8.2; p ¼ 0.02), adjacent to but
not including the critical region of Prader-Willi/Angelman
syndrome (MIM 176270). These deletions implicated four
RefSeq genes, none of which have been previously associ-
ated with CHD. However, TUBGCP5 and NIPA1 were
reportedly expressed in the fetal heart (Bgee database),The American Journal of Human Genethus increasing their candidacy as
the causative gene for CHD. Of note,
half of the cases with deletions had
left-sided cardiac lesions; study of
larger numbers of cases will be
required for determining the signifi-
cance of this apparent subphenotypic
predominance. A previous study of
182 individuals with left ventricular
outflow-tract obstruction identified
the same 15q11.2 deletion in one
person.27 Cooper et al.4 recently iden-
tified such deletions in 6 out of 575
CHD cases in their cohort (p ¼ 0.004
when compared to controls). The
penetrance of CHD associated withsuch deletions is clearly incomplete; only two out of nine
individuals with the deletion reported in a study by
Doornbos et al. had heart defects,28 and both we and
Cooper et al. observed the deletion in healthy controls.
Previously, 15q11.2 deletions have been associated with
idiopathic generalized epilepsies,29 schizophrenia,30 and
behavioral disturbances,28 and point mutations in NIPA1,
one of the genes in the critical region, are known to cause
autosomal-dominant spastic paraplegia.31 Our results
suggest that, after the previously described 1q21.1 CNVs
associated with TOF and other forms of CHD, the
15q11.2 deletion is the CNV most strongly associated
with the risk of sporadic, nonsyndromic CHD. Confirma-
tion of our findings at this region in further large studies
would be of considerable interest.
Deletion of a 8p23 5Mb region that encompassesGATA4
has previously been associated with multiple malforma-
tions that include CHD.32 GATA4 is a transcription factor
essential for cardiac development.33 The first GATA4muta-
tions reported were in two pedigrees withmultiple affected
family members; in both families, all affected individuals
had atrial septal defects, but in the larger pedigree, half
had additional cardiac abnormalities, including pulmo-
nary stenosis, ventricular septal defects, atrioventricular
septal defects, and aortic regurgitation.34 In our CHD cases,
we observed four deletions and one duplication of 8p23.1tics 91, 489–501, September 7, 2012 495
Table 6. Rare De Novo CNVs Identified in 283 TOF Trios
Family ID Sex
Age
(Years) Cytoband
Hg18 Start
Coordinate Length CN Origin RefSeq Genes
Cardiac and
Extracardiac
Phenotype
CHA-91 male 10 4q34.1-
q34.3
173,538,773 6,551,325 del P GALNTL6, GALNT7, HMGB2, SAP30,
SCRG1, HAND2, NBLA00301, MORF4,
FBXO8, KIAA1712, MIR4276, HPGD,
GLRA3, ADAM29, GPM6A, MIR1267,
WDR17, SPATA4, ASB5, SPCS3,
VEGFC, NEIL3, AGA, LOC285501
TOF, asthma,
bilateral
cryptorchidism
FCH-306 male 1 3q29 197,168,088 1,660,486 del P SDHAP1, TFRC, LOC401109, ZDHHC19,
OSTa, PCYT1A, TCTEX1D2, TM4SF19,
UBXN7, RNF168, C3orf43,WDR53,
FBXO45, LRRC33, C3orf34, PIGX,
PAK2, SENP5, NCBP2, LOC152217,
PIGZ, MFI2, DLG1, BDH1
TOF, interrupted
aortic arch,
chest deformity
(sternum)
CHA-617 female 10 16q24.2 85,737,889 177,523 del P C16orf95 TOF
NOTT-189b female 1 6q27 167,037,829 67,836 del P RPS6KA2 TOF
CHA-767 male 3 19p13.3 252,619 52,630 del P MIER2 TOF with MAPCA
CHA-25 female 54 16q11.2 45,056,281 40,613 del N/A ANKRD26P1 TOF
CHA-64a male 13 22q12.3 31,789,131 188,778 del M none TOF
CHA-812 male 8 3q13.11 105,183,599 97,653 del P none TOF, asthma
CHA-137 female 1 1q21.1 144,967,972 1,418,624 dup P LOC728989, PRKAB2, PDIA3P, FMO5,
CHD1L, BCL9, ACP6, GJA5, GJA8
TOF,
laryngomalacia
CHA-9 female 3 5q14.1-
q14.3
80,936,354 4,937,263 dup P SSBP2, TMEM167A, SCARNA18,
XRCC4, VCAN, HAPLN1, EDIL3
TOF
NOTT-389 male 1 9p22.2 17,735,053 50,117 dup N/A SH3GL2 TOF
CHA-750 female 2 5q35.3 179,681,237 432,453 dup P GFPT2, CNOT6, SCGB3A1,
FLT4, OR2Y1
TOF
CHA-817 male 16 5q35.3 178,357,798 264,665 dup P ZNF879, ZNF354C, ADAMTS2 TOF
Genes in bold are reported to be expressed in the fetal heart (Bgee database), except for SH3GL2, whose expression was detectable in the early embryo and in the
myocardium of the child and adult heart. The following abbreviations are used: del, deletion; dup, duplication; P, paternal; M, maternal; N/A, not available; TOF,
Tetralogy of Fallot; and MAPCA, major aortopulmonary collateral arteries.and a critical region spanning four genes, including
GATA4. The cardiac phenotypes were atrioventricular
septal defects (n ¼ 1), ventricular septal defects (n ¼ 1),
and TOF (n ¼ 2) in the deleted individuals and a bicuspid
aortic valve with aortic regurgitation in the case with the
duplication. GATA4 missense changes have previously
been detected at low frequencies in cases of TOF.35,36
Comparison of CNV frequency between our cases and
controls did not achieve statistical significance (p ¼
0.08). Cooper et al. reported three deletions and one dupli-
cation that spanned GATA4 in their 575 CHD individuals,
whereas they found no deletions or duplications encom-
passing GATA4 in their 8,329 controls (p ¼ 1.7 3 105 by
Fisher’s two-tailed exact test).4 Furthermore, there are no
reports of CNVs overlapping GATA4 in any of the control
populations that have been cataloged in the DGV. Consid-
ering these data in the context of the previously demon-
strated causative nature of GATA4 missense mutations in
CHD, we conclude that it is highly likely that the CHD
phenotypes observed in our five individuals with 8p23.1
CNVs resulted from dosage sensitivity of GATA4.
We observed a global rare de novo CNV burden of ~5%
in our 283 TOF trios. This is broadly concordant with496 The American Journal of Human Genetics 91, 489–501, Septembthat previously reported in another cohort of 114 TOF
trios7 given the differences in the genotyping platforms
and analysis pipelines between the two studies. The rare
de novo CNVs identified in this study implicate known
candidate loci (1q21.1, 3q29, and 4q34), as well as other
loci (3q13.11, 5q14, 5q35.3, 6q27, 9p22.2, 16q11.2,
16q24.2, 19p13.3, and 22q12.3) that have not been
previously associated with CHD with recurring CNVs
in 1q21.1 (GJA5), 4q34 (HAND2), 5q14.2 (EDIL3), and
5q35.3 (CNOT6).
The distal 1q21.1 locus has been previously shown to
manifest a degree of phenotypic specificity in CHD, as
well as in other developmental phenotypes. Duplications
of 1q21.1 are associated with TOF, autism, and macroce-
phaly, whereas the reciprocal deletions are associated
with other types of (non-TOF) CHD, schizophrenia, and
microcephaly.8,37,38 Previous studies in mice and humans
strongly suggest that GJA5, which encodes connexin-40,
is the critical gene for the CHD phenotype in this
locus.8,39 The rare de novo deletion found in one indi-
vidual at the 4q34 locus spanned 24 RefSeq genes (see
Table 5). One of the deleted genes was HAND2, which
encodes a basic helix-loop-helix transcription factorer 7, 2012
Figure 3. Rare CNVs Overlapping Rare
De Novo CNVs Identified in TOF Trios
We examined the remaining 1,978 CHD
cases for recurrent CNVs that overlap rare
de novo findings in 283 TOF trios. We
found overlaps in 4q34 (a rare deletion
in the highly conserved region upstream
of HAND2, as shown in A), 5q14.2
(one rare deletion overlapping EDIL3
and two others overlapping a conserved
region ~100 kb upstream of EDIL3, as
shown in B), and 5q35 (an deletion over-
lapping CNOT6, as shown in C). Deletions
and duplications are shown in the UCSC
Genome Browser as red and blue bars,
respectively. The following abbreviations
are used: PS, pulmonary stenosis; and
VSD, ventricular septal defect.known for its pivotal roles in cardiac development.40 The
500 kb overlapping deletion that was found in another
individual with TOF, however, did not span the coding
region of HAND2 but did encompass a highly conserved
region that is ~100 kb upstream of HAND2 and that over-
laps previously predicted human heart-specific enhancer
sequences.41 Although this deletion was inherited from
an unaffected father, we did not find overlapping
CNVs in our 1,577 controls or in the DGV. It is known
that some CNVs in noncoding segments can profoundly
affect the expression of copy-number neutral genes in
the vicinity.42 Thus, taking into account the large size
(>500 kb) of the deletion, its rarity, and the high degree
of conservation of the involved region, we consider thisThe American Journal of Human Genedeletion highly likely to have contrib-
uted to the occurrence of CHD in this
individual (Figure 3 and Table S7).
We also identified recurrent CNVs
at the 5q35.3 locus (Figure 3). The
overlapping segment spanned a
single gene: CNOT6, which encodes
a subunit of the CCR4-NOT core tran-
scriptional complex, which is known
to be crucial for controlling mRNA
stability during embryonic develop-
ment.43,44 RNAi silencing of dNOT3,
another subunit of the same com-
plex, in Drosophila and heterozygous
knockout of Cnot3 in mice both re-
sulted in heart defects.45We addition-
ally found three cases with deletions
overlapping the rare de novo duplica-
tion in the 5q14 locus. One of the
deletions that spanned the last two
exons of EDIL3 was found in a 62-
year-old participant with pulmonary
stenosis and a secundum atrial septal
defect. The other two individuals,
who had a deletion situated ~100 kb
upstream of EDIL3, were an 8-year-old with TOF and an 11-year-old with a ventricular septal
defect. Glessner et al. reported the same deletion variant
upstream of EDIL3 in childhood-obesity cases (6 of 2,559
cases and 0 of 4,075 lean controls); the CHD status of
these cases was not reported.46 This variant was not
present in our 1,578 controls or in the DGV. Both of
the participants with these deletions had no notable ex-
tracardiac phenotypes. EDIL3 (epidermal growth-factor-
like repeats and discoidin I-like domains 3) encodes a glyco-
protein secreted by endothelial cells. It plays an important
role in vessel-wall remodeling and development during
angiogenesis.47,48 It is also upregulated in cardiac progen-
itor cells, supporting a potential role in early cardiac devel-
opment; this role merits further investigation.49tics 91, 489–501, September 7, 2012 497
Figure 4. Rare CNVs Overlapping CNVs
Reported by Greenway et al., 2009
We searched in 1,987 CHD cases for CNVs
overlapping the rare de novo CNVs previ-
ously reported by Greenway et al. We
found recurrent rare deletions in the
7p21.3 locus (A) in two TOF probands,
both of whom inherited the deletions
from their respective unaffected fathers.
Both of these findings had been confirmed
on the Affymetrix 6.0 platform and by
MLPA. We did not find such variants in
841 unrelated controls or other unaffected
family members (n ¼ 695). These rare
CNVs did not overlap any known RefSeq
genes, although there are some overlaps
with transcription-factor binding-site
conservation (shown). The nearest gene
is NXPH1.
(B) On the Illumina 660W platform
(shown), there is insufficient coverage
overlapping the 4q22.1 de novo variant
reported by Greenway et al. Therefore, in
addition to examining this locus in the
1,987 CHD probands who had been typed
on the Illumina 660W, we also screened
this locus with MLPA in 1,007 CHD cases, 866 of whom were also typed on the Illumina 660W. In a TOF proband, we detected a dupli-
cation that encompassed PPM1K (as shown). No overlapping duplication was found in 841 unrelated controls or 697 unaffected family
members. The parental DNA samples of this proband were not available for analysis. Deletions and duplications are shown in the UCSC
Genome Browser as red and blue bars, respectively.With the exception of 1q21.1, we did not replicate the
de novo findings that were reported by Greenway et al.
in our TOF trios.7 However, in the remaining 1,987 CHD
cases, we found rare CNVs overlapping those reported by
Greenway et al. at 7p21.3 and 4q22.1, thus supporting
the notion that they are involved in CHD risk. There is
no RefSeq gene that overlaps the 7p21.3 locus, in which
we found deletions of paternal origin in two TOF cases
(Figure 4). The nearest gene is NXPH1 (MIM 604639),
a neurexophilin family member that promotes adhesion
between dendrites and axons. This region has been previ-
ously associated with autism and attention-deficit-hyper-
active disorder.50 The overlapping duplication in the
4q22.1 locus, on the other hand, spanned a single gene,
PPM1K (PP2C domain-containing protein phosphatase
1K or PP2C-like mitochondrial protein phosphatase
[MIM 611065]), which is essential for cell survival, embry-
onic development, and cardiac function. Knockdown of
this gene in zebrafish embryos resulted in abnormal
cardiac development and heart failure from induced
apoptosis.51
Interestingly, 10 out of 11 rare de novo CNVs identified
in our TOF trios occurred on the paternally transmitted
chromosome (p ¼ 0.01). A recent study reported a similar
magnitude of paternal bias in the origin of rare de novo
CNVs in 3,443 individuals with intellectual disability
(90 of 118 paternal; p ¼ 1.14 3 108).20 In that study,
the median paternal age of those with rare de novo
CNVs that were not flanked with SDs (which represented
~80% of deletions detected) was slightly higher (34.16 5
4.91 years) than that of those not carrying such CNVs498 The American Journal of Human Genetics 91, 489–501, Septemb(32.13 5 4.17 years; p ¼ 0.02). A similar finding was
reported in a study of 173 individuals with multisystem
abnormalities:21 an excess of paternal origin in non-SD-
mediated de novo CNV events (p ¼ 0.02) was seen. No
increased paternal-age bias was detected in that study,
although this might have been due to a lack of power.
SD-mediated chromosomal rearrangement is known to
be the primary generating mechanism for CNVs,52,53 but
in keeping with these two reports, most of the rare de
novo CNV breakpoints in our study did not coincide
with directly oriented SDs (Figure S3). A higher rate of
non-SD-mediated mechanisms—e.g., nonhomologous-
end joining (NHEJ) and fork stalling and template switch-
ing (FoSTeS)—as a result of the increased occurrence of
double-strand breaks resulting from the greater number
of germ cell divisions in spermatogenesis compared to
oogenesis (particularly in older males) has been proposed
as a mechanism whereby this could occur.54 Advanced
paternal age has been suggested to be an independent
risk factor for CHD.55 However, the number of de novo
CNVs in our study was too small for any meaningful statis-
tical analysis of paternal age to be conducted.
Considering the acknowledged limitations of the
currently available CNV-detection technologies, we opted
to take a conservative approach in our global CNV anal-
yses. All of our case and control subjects were typed on
the same platform at the same genotyping center, and we
adopted highly stringent CNV-calling criteria in order to
ensure comparability in detection between samples origi-
nating from multiple clinical centers. We further under-
took extensive validation experiments in order to identifyer 7, 2012
the regions that cannot be accessed reliably with our detec-
tion platform, and we excluded them from our analyses.
Our approach thus effectively minimized false-positive
discoveries in our data set, albeit at the expense of a higher
false-negative rate. We adopted a different strategy in our
search for potential highly penetrant rare de novo CNVs
in our TOF trios by significantly lowering the stringency
of our CNV-calling criteria in order to maximize capture.
However, we subjected all putative CNVs identified by
these latter criteria to confirmation with one or more inde-
pendent methods. Therefore, we have high confidence in
the CNV calls in both the case-control and trio arms of
the study.
Our study firmly established the collective contribution
of global rare CNVs to the risk of sporadic CHD. However,
the bulk of our findings constitute single-occurrence
CNVs, whose associations with CHD at each individual
locus cannot be statistically evaluated. It is likely that
large-scale meta-analyses of tens of thousands of partici-
pants will be required for accurately characterizing
associations of these very rare CNVs. Moreover, the pheno-
typic composition of our cohort was heterogeneous and
included relatively few cases of rarer malformations (e.g.,
hypoplastic left heart syndrome and heterotaxy). For these
rare lesions, further studies involving larger numbers will
be of value. We detected recurrent CNVs spanning indi-
vidual genes (EDIL3 and CNOT6), which are therefore
strong candidates for CHD. However, most of the recurrent
rare CNVs, including the 15q11.2 deletions, for which we
detected an association with CHD, identified in this study
spanned multiple genes. Therefore, functional studies for
characterizing the role in heart development of genes
within the CNVs identified in this study are a priority for
future work; among these, strongly predicted dosage-
sensitive genes (those with high haploinsufficiency scores)
are of particular interest. Identification of causative genes
for CHD and characterization of the magnitude of their
relationship with risk could potentially lead to improve-
ment in genetic counseling in families with a high risk
of CHD—perhaps particularly in CHD-affected adults
contemplating reproductive choices.Supplemental Data
Supplemental Data include three figures and eight tables and can
be found with this article online at http://www.cell.com/AJHG.Acknowledgments
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